|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,800 KRW | -0.10% |
|
-1.84% | -15.79% |
| 2023 | Korea Arlico Pharm Co.,Ltd. announced that it has received KRW 10 billion in funding | CI |
| 2023 | Korea Arlico Pharm Co.,Ltd. announced that it expects to receive KRW 10 billion in funding | CI |
Korea Arlico Pharm Co.,Ltd. (KOSDAQ:A260660) announces a share repurchase program. Under the program, the company will repurchase up to 64,000 shares. The purpose behind the program is stock price stability and shareholder value enhancement.
The repurchase program will expire on January 6, 2022. As of October 5, 2021, the company had 249,630 treasury shares within scope available for dividend and no shares in treasury through other repurchase.
| 1st Jan change | Capi. | |
|---|---|---|
| -15.79% | 53.12M | |
| +20.76% | 43.59B | |
| +28.00% | 22.54B | |
| +20.25% | 15.73B | |
| +18.82% | 14.33B | |
| +55.83% | 12.75B | |
| -0.05% | 6.79B | |
| -12.70% | 6.48B | |
| -8.87% | 5.73B | |
| +14.65% | 5.67B |
KOREA ARLICO PHARM CO.,LTD. 
